SFS 2013:640 Förordning om ändring i förordningen (1992:1554) om kontroll av narkotika

<div><style type="text/css"> <!-- p {margin: 0; padding: 0;} .ft10{font-size:14px;font-family:BLANEB+TimesNewRomanPS;color:#000000;} .ft11{font-size:27px;font-family:BLANFC+TimesNewRomanPS;color:#000000;} .ft12{font-size:19px;font-family:BLANFC+TimesNewRomanPS;color:#000000;} .ft13{font-size:8px;font-family:BLANEB+TimesNewRomanPS;color:#000000;} .ft14{font-size:7px;font-family:BLANEB+TimesNewRomanPS;color:#000000;} .ft15{font-size:12px;font-family:BLANEB+TimesNewRomanPS;color:#000000;} .ft16{font-size:19px;line-height:19px;font-family:BLANFC+TimesNewRomanPS;color:#000000;} .ft17{font-size:14px;line-height:17px;font-family:BLANEB+TimesNewRomanPS;color:#000000;} .ft18{font-size:12px;line-height:14px;font-family:BLANEB+TimesNewRomanPS;color:#000000;} .ft19{font-size:12px;line-height:12px;font-family:BLANEB+TimesNewRomanPS;color:#000000;} .ft110{font-size:12px;line-height:15px;font-family:BLANEB+TimesNewRomanPS;color:#000000;} --> <!-- p {margin: 0; padding: 0;} .ft20{font-size:14px;font-family:BLANEB+TimesNewRomanPS;color:#000000;} .ft21{font-size:15px;font-family:BLANFC+TimesNewRomanPS;color:#000000;} .ft22{font-size:14px;font-family:BLANIE+TimesNewRomanPS;color:#000000;} .ft23{font-size:8px;font-family:BLANEB+TimesNewRomanPS;color:#000000;} .ft24{font-size:14px;font-family:BLANFC+TimesNewRomanPS;color:#000000;} .ft25{font-size:14px;font-family:BLANIF+SymbolMT;color:#000000;} .ft26{font-size:7px;font-family:BLANEB+TimesNewRomanPS;color:#000000;} .ft27{font-size:12px;font-family:BLANEB+TimesNewRomanPS;color:#000000;} .ft28{font-size:14px;line-height:17px;font-family:BLANFC+TimesNewRomanPS;color:#000000;} .ft29{font-size:14px;line-height:17px;font-family:BLANEB+TimesNewRomanPS;color:#000000;} --> <!-- p {margin: 0; padding: 0;} .ft30{font-size:14px;font-family:BLANEB+TimesNewRomanPS;color:#000000;} .ft31{font-size:15px;font-family:BLANFC+TimesNewRomanPS;color:#000000;} .ft32{font-size:14px;font-family:BLANIE+TimesNewRomanPS;color:#000000;} .ft33{font-size:14px;line-height:17px;font-family:BLANEB+TimesNewRomanPS;color:#000000;} --> <!-- p {margin: 0; padding: 0;} .ft40{font-size:14px;font-family:BLANEB+TimesNewRomanPS;color:#000000;} .ft41{font-size:15px;font-family:BLANFC+TimesNewRomanPS;color:#000000;} .ft42{font-size:14px;font-family:BLANIE+TimesNewRomanPS;color:#000000;} .ft43{font-size:14px;line-height:17px;font-family:BLANEB+TimesNewRomanPS;color:#000000;} --> <!-- p {margin: 0; padding: 0;} .ft50{font-size:14px;font-family:BLANEB+TimesNewRomanPS;color:#000000;} .ft51{font-size:15px;font-family:BLANFC+TimesNewRomanPS;color:#000000;} .ft52{font-size:8px;font-family:BLANEB+TimesNewRomanPS;color:#000000;} .ft53{font-size:7px;font-family:BLANEB+TimesNewRomanPS;color:#000000;} .ft54{font-size:12px;font-family:BLANEB+TimesNewRomanPS;color:#000000;} .ft55{font-size:14px;line-height:17px;font-family:BLANEB+TimesNewRomanPS;color:#000000;} --> <!-- p {margin: 0; padding: 0;} .ft60{font-size:8px;font-family:BLANEB+TimesNewRomanPS;color:#000000;} --> </style> <div id="page1-div" style="position:relative;width:701px;height:1028px;"> <img width="701" height="1028" src="/Static/i/lagboken/hidden.png" alt="background image"/> <p style="position:absolute;top:924px;left:646px;white-space:nowrap" class="ft10">1</p> <p style="position:absolute;top:80px;left:77px;white-space:nowrap" class="ft11"><b>Svensk f�rfattningssamling</b></p> <p style="position:absolute;top:187px;left:77px;white-space:nowrap" class="ft16"><b>F�rordning<br/>om �ndring i f�rordningen (1992:1554) om kontroll <br/>av narkotika;</b></p> <p style="position:absolute;top:263px;left:77px;white-space:nowrap" class="ft10">utf�rdad den 19 juni 2013.</p> <p style="position:absolute;top:298px;left:91px;white-space:nowrap" class="ft10">Regeringen f�reskriver</p> <p style="position:absolute;top:296px;left:222px;white-space:nowrap" class="ft13">1 att bilaga 1 till f�rordningen (1992:1554) om kont-</p> <p style="position:absolute;top:315px;left:77px;white-space:nowrap" class="ft10">roll av narkotika</p> <p style="position:absolute;top:313px;left:171px;white-space:nowrap" class="ft13">2 ska ha f�ljande lydelse.</p> <p style="position:absolute;top:351px;left:91px;white-space:nowrap" class="ft10">Denna f�rordning tr�der i kraft den 1 augusti 2013.</p> <p style="position:absolute;top:386px;left:77px;white-space:nowrap" class="ft10">P� regeringens v�gnar</p> <p style="position:absolute;top:421px;left:77px;white-space:nowrap" class="ft10">MARIA LARSSON</p> <p style="position:absolute;top:438px;left:307px;white-space:nowrap" class="ft17">Lars Hedengran<br/>(Socialdepartementet)</p> <p style="position:absolute;top:872px;left:77px;white-space:nowrap" class="ft19">1 Se Europaparlamentets och r�dets direktiv 98/34/EG av den 22 juni 1998 om ett in-<br/>formationsf�rfarande betr�ffande tekniska standarder och f�reskrifter (EGT L 204,<br/>21.7.1998, s. 37, Celex 31998L0034), �ndrat genom r�dets direktiv 98/48/EG (EGT L<br/>217, 5.8.1998, s. 18, Celex 31998L0048).</p> <p style="position:absolute;top:923px;left:77px;white-space:nowrap" class="ft14">2 F�rordningen omtryckt 1993:784.</p> <p style="position:absolute;top:175px;left:536px;white-space:nowrap" class="ft12"><b>SFS 2013:640</b></p> <p style="position:absolute;top:202px;left:536px;white-space:nowrap" class="ft110">Utkom fr�n trycket<br/>den 2 juli 2013</p> </div> <div id="page2-div" style="position:relative;width:701px;height:1028px;"> <img width="701" height="1028" src="/Static/i/lagboken/hidden.png" alt="background image"/> <p style="position:absolute;top:924px;left:46px;white-space:nowrap" class="ft20">2</p> <p style="position:absolute;top:51px;left:46px;white-space:nowrap" class="ft21"><b>SFS 2013:640</b></p> <p style="position:absolute;top:51px;left:571px;white-space:nowrap" class="ft22"><i>Bilaga 1</i></p> <p style="position:absolute;top:49px;left:619px;white-space:nowrap" class="ft23">3</p> <p style="position:absolute;top:94px;left:181px;white-space:nowrap" class="ft28"><b>F�rteckning �ver substanser som ska anses som narkotika enligt <br/>narkotikastrafflagen</b></p> <p style="position:absolute;top:138px;left:181px;white-space:nowrap" class="ft22"><i>Centralstimulerande medel</i></p> <p style="position:absolute;top:164px;left:196px;white-space:nowrap" class="ft29">etylamfetamin (2-etylamino-1-fenylpropan)<br/>fenetyllin<br/>[1-fenyl-1-piperidyl-(2)-metyl]acetat<br/>1-fenyl-2-butylamin<br/>N-hydroxiamfetamin<br/>propylhexedrin<br/>4-metyltioamfetamin (4-MTA)<br/>modafinil<br/>4-metoxi-N-metylamfetamin (PMMA, 4-MMA)<br/>2,5-dimetoxi-4-etyltiofenetylamin (2C-T-2)<br/>2,5-dimetoxi-4-(n)-propyltiofenetylamin (2C-T-7)<br/>4-jodo-2,5-dimetoxifenetylamin (2C-I)<br/>2,4,5-trimetoxiamfetamin (TMA-2)<br/>4-metylmetkatinon (mefedron)<br/>4-fluoramfetamin<br/>1-(4-metoxifenyl)-2-(metylamino)propan-1-on (metedron)<br/>1-(1,3-bensodioxol-5-yl)-2-pyrrolidin-1-yl-pentan-1-on (MDPV)<br/>1-(1,3-bensodioxol-5-yl)-2-(metylamino)butan-1-on (butylon)<br/>1-bensylpiperazin (N-bensylpiperazin)<br/>2-metylamino-1-(3,4-metylendioxifenyl)propan-1-on (metylon)<br/>1-(naftalen-2-yl)-2-pyrrolidin-1-yl-pentan-1-on (nafyron)<br/>2-etylamin-1-fenyl-propan-1-on (N-etylkatinon)<br/>1-(2-fluorfenyl)-2-(metylamino)propan-1-on<br/>1-(3-fluorfenyl)-2-(metylamino)propan-1-on<br/>1-(4-fluorfenyl)-2-(metylamino)propan-1-on (flefedron)<br/>2-benshydrylpiperidin (desoxipipradol)<br/>metyl(E)-2-[(2S,3S,12bS)-3-etyl-8-metoxi-1,2,3,4,6,7,12,12b-oktahy-</p> <p style="position:absolute;top:634px;left:181px;white-space:nowrap" class="ft20">droindol[2,3-a]quinolizin-2-yl]-3-metoxiprop-2-enoat (mitragynin)</p> <p style="position:absolute;top:651px;left:196px;white-space:nowrap" class="ft29">(8-metyl-8-azabicyklo[3.2.1]oktan-3-yl)-4-flourbensoat (pFBT)<br/>2-etylamin-1-(4-metylfenyl)-1-propanon (4-MEC)<br/>2-metylamin-1-fenylbutan-1-on (bufedron)<br/>etyl-2-fenyl-2-(piperidin-2-yl)acetat (etylfenidat)<br/>1-(4-metylfenyl)propan-2-amin <i>(</i>4-MA)<br/>1-fenyl-2-(1-pyrrolidinyl)-1-propanon (</p> <p style="position:absolute;top:734px;left:422px;white-space:nowrap" class="ft25">a-PPP)</p> <p style="position:absolute;top:756px;left:196px;white-space:nowrap" class="ft20">1-fenyl-2-(pyrrolidin-1-yl)-pentan-1-on (</p> <p style="position:absolute;top:751px;left:430px;white-space:nowrap" class="ft25">a-PVP)</p> <p style="position:absolute;top:773px;left:196px;white-space:nowrap" class="ft29">1-fenyl-2-(metylamino)-pentan-1-on (pentedron)<br/>(2S)-2,6-diamino-N-[(2S)-1-fenylpropan-2-yl]hexanamid </p> <p style="position:absolute;top:808px;left:181px;white-space:nowrap" class="ft20">(lisdexamfetamin)</p> <p style="position:absolute;top:825px;left:196px;white-space:nowrap" class="ft20">1-(2-fluorofenyl)-N-metylpropan-2-amin (2-fluorometamfetamin, </p> <p style="position:absolute;top:843px;left:181px;white-space:nowrap" class="ft20">2-FMA)</p> <p style="position:absolute;top:860px;left:196px;white-space:nowrap" class="ft20">1-(3-fluorofenyl)-N-metylpropan-2-amin (3-fluorometamfetamin, </p> <p style="position:absolute;top:877px;left:181px;white-space:nowrap" class="ft20">3-FMA)</p> <p style="position:absolute;top:921px;left:181px;white-space:nowrap" class="ft26">3 Senaste lydelse 2013:523.</p> </div> <div id="page3-div" style="position:relative;width:701px;height:1028px;"> <img width="701" height="1028" src="/Static/i/lagboken/hidden.png" alt="background image"/> <p style="position:absolute;top:924px;left:649px;white-space:nowrap" class="ft30">3</p> <p style="position:absolute;top:51px;left:536px;white-space:nowrap" class="ft31"><b>SFS 2013:640</b></p> <p style="position:absolute;top:51px;left:91px;white-space:nowrap" class="ft30">1-(4-fluorofenyl)-N-metylpropan-2-amin (4-fluorometamfetamin, </p> <p style="position:absolute;top:68px;left:77px;white-space:nowrap" class="ft30">4-FMA)</p> <p style="position:absolute;top:85px;left:91px;white-space:nowrap" class="ft33">1-(2-fluorofenyl)propan-2-amin (2-fluoroamfetamin)<br/>1-(3-fluorofenyl)propan-2-amin<i> </i>(3-fluoroamfetamin)</p> <p style="position:absolute;top:146px;left:77px;white-space:nowrap" class="ft32"><i>Hallucinogener</i></p> <p style="position:absolute;top:173px;left:91px;white-space:nowrap" class="ft33">2-amino-1-(4-brom-2,5-dimetoxifenyl)propan (brom-STP)<br/>hydroxi-3-pentyl-6,6,9-trimetyl-6a,7,10,10a-tetrahydro-6H-dibenso[b,d]</p> <p style="position:absolute;top:208px;left:77px;white-space:nowrap" class="ft30">pyranol-(1) (hydroxitetrahydrocannabinoler)</p> <p style="position:absolute;top:225px;left:91px;white-space:nowrap" class="ft33">ibogain<br/>levonantradol<br/>nabilon <br/>4-jod-2,5-dimetoxiamfetamin (DOI)<br/>4-klor-2,5-dimetoxiamfetamin (DOC)<br/>brombensodifuranylisopropylamin (Bromo-Dragonfly)<br/>dextrometorfan med undantag f�r beredningar f�r medicinskt eller veten-</p> <p style="position:absolute;top:347px;left:77px;white-space:nowrap" class="ft30">skapligt bruk i form av l�sningar som inte inneh�ller mer �n 3 mg/ml</p> <p style="position:absolute;top:364px;left:91px;white-space:nowrap" class="ft30">5-(1,1-Dimethylhexyl)-2-((1R,3S)-3-hydroxycyclohexyl)-phenol</p> <p style="position:absolute;top:382px;left:77px;white-space:nowrap" class="ft30">(CP47,497-C6)</p> <p style="position:absolute;top:399px;left:91px;white-space:nowrap" class="ft30">5-(1,1-Dimethylheptyl)-2-((1R,3S)-3-hydroxycyclohexyl)-phenol</p> <p style="position:absolute;top:416px;left:77px;white-space:nowrap" class="ft30">(CP47,497-C7)</p> <p style="position:absolute;top:434px;left:91px;white-space:nowrap" class="ft30">5-(1,1-Dimethyloctyl)-2-((1R,3S)-3-hydroxycyclohexyl)-phenol</p> <p style="position:absolute;top:451px;left:77px;white-space:nowrap" class="ft30">(CP47,497-C8)</p> <p style="position:absolute;top:469px;left:91px;white-space:nowrap" class="ft30">5-(1,1-Dimethylnonyl)-2-((1R,3S)-3-hydroxycyclohexyl)-phenol</p> <p style="position:absolute;top:486px;left:77px;white-space:nowrap" class="ft30">(CP47,497-C9)</p> <p style="position:absolute;top:503px;left:91px;white-space:nowrap" class="ft33">Naphthalene-1-yl-(1-pentylindol-3-yl)methanon (JWH-018)<br/>Naphthalene-1-yl-(1-butylindol-3-yl)methanon (JWH-073)<br/>4-metoxinaftalen-1-yl-(1-pentylindol-3-yl)metanon (JWH-081)<br/>4-metylnaftalen-1-yl-(1-pentylindol-3-yl)metanon (JWH-122)<br/>[1-[2-(4-morfolinyl)etyl]-1H-indol-3-yl]-1-naftalenylmetanon (JWH-200)<br/>2-(2-klorophenyl)-1-(1-pentylindol-3-yl)etanon (JWH-203)<br/>4-etylnaftalen-1-yl-(1-pentylindol-3-yl)metanon (JWH-210)<br/>2-(2-metoxifenyl)-1-(1-pentyl-1H-indol-3-yl)etanon (JWH-250)<br/>(4-klornaftalen-1-yl)(1-pentyl-1H-indol-3-yl)metanon (JWH-398)<br/>(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)</p> <p style="position:absolute;top:677px;left:77px;white-space:nowrap" class="ft30">6a,7,10,10a,tetrahydrobenzo[c]chromen-1-ol) (HU-210)</p> <p style="position:absolute;top:695px;left:91px;white-space:nowrap" class="ft33">(2-metoxifenyl)(1-pentyl-1H-indol-3-yl)metanon (RCS-4 orto isomer)<br/>2-(etylamino)-2-(3-metoxifenyl)cyklohexanon (metoxetamin)<br/>1-[(5-fluoropentyl)-1H-indol-3-yl]-(naftalen-1-yl)metanon (AM-2201)<br/>1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-jodofenyl)metanon (AM-694)<br/>N-allyl-N-[2-(5-metoxi-1H-indol-3-yl)etyl]-prop-2-en-1-amin </p> <p style="position:absolute;top:782px;left:77px;white-space:nowrap" class="ft30">(5-MeO-DALT)</p> <p style="position:absolute;top:799px;left:91px;white-space:nowrap" class="ft33">3-[2-[etyl(metyl)amino]etyl]-1H-indol-4-ol (4-HO-MET)<br/>(1-(5-fluoropentyl)-1H-indol-3-yl)(4-metyl-1-naftalen-1-yl)metanon</p> <p style="position:absolute;top:834px;left:77px;white-space:nowrap" class="ft30">(MAM-2201)</p> <p style="position:absolute;top:851px;left:91px;white-space:nowrap" class="ft30">(1-((1-metylpiperidin-2-yl)metyl)-1H-indol-3-yl)(naftalen-1-yl)-metanon</p> <p style="position:absolute;top:869px;left:77px;white-space:nowrap" class="ft30">(AM-1220)</p> <p style="position:absolute;top:886px;left:91px;white-space:nowrap" class="ft30">(2-jodofenyl)(1-((1-metylpiperidin-2-yl)metyl)-1H-indol-3-yl)metanon</p> <p style="position:absolute;top:904px;left:77px;white-space:nowrap" class="ft30">(AM-2233)</p> </div> <div id="page4-div" style="position:relative;width:701px;height:1028px;"> <img width="701" height="1028" src="/Static/i/lagboken/hidden.png" alt="background image"/> <p style="position:absolute;top:924px;left:46px;white-space:nowrap" class="ft40">4</p> <p style="position:absolute;top:51px;left:46px;white-space:nowrap" class="ft41"><b>SFS 2013:640</b></p> <p style="position:absolute;top:51px;left:196px;white-space:nowrap" class="ft43">2-(4-jodo-2,5-dimetoxifenyl)-N-(2-metoxibensyl)etanamin (25I-NBOMe)<br/>2-(4-kloro-2,5-dimetoxifenyl)-N-(2-metoxibensyl)etanamin </p> <p style="position:absolute;top:85px;left:181px;white-space:nowrap" class="ft40">(25C-NBOMe)</p> <p style="position:absolute;top:103px;left:196px;white-space:nowrap" class="ft40">2-(4-bromo-2,5-dimetoxifenyl)-N-(2-metoxibensyl)etanamin </p> <p style="position:absolute;top:120px;left:181px;white-space:nowrap" class="ft40">(25B-NBOMe)</p> <p style="position:absolute;top:138px;left:196px;white-space:nowrap" class="ft40">2-(2,5-dimetoxi-4-metylfenyl)-N-(2-metoxibensyl)etanamin </p> <p style="position:absolute;top:155px;left:181px;white-space:nowrap" class="ft40">(25D-NBOMe)</p> <p style="position:absolute;top:172px;left:196px;white-space:nowrap" class="ft43">2-(2,5-dimetoxifenyl)-N-(2-metoxibensyl)etanamin (25H-NBOMe)<br/>(1-(5-fluoropentyl)-1H-indol-3-yl)(4-etyl-naftalen-1-yl)metanon </p> <p style="position:absolute;top:207px;left:181px;white-space:nowrap" class="ft40">(EAM-2201)</p> <p style="position:absolute;top:251px;left:181px;white-space:nowrap" class="ft42"><i>Sm�rtstillande medel</i></p> <p style="position:absolute;top:277px;left:196px;white-space:nowrap" class="ft43">karfentanil<br/>karisoprodol<br/>remifentanil<br/>gamma-hydroxi-butyrat (GHB)<br/>ketamin<br/>tapentadol<br/>tramadol <br/>O-desmetyltramadol (ODT)<br/>3,4-dikloro-N-[[1-(dimetylamino)cyklohexyl]metyl]bensamid (AH-7921)</p> <p style="position:absolute;top:460px;left:181px;white-space:nowrap" class="ft42"><i>S�mnmedel och lugnande medel</i></p> <p style="position:absolute;top:486px;left:196px;white-space:nowrap" class="ft43">allobarbital<br/>aprobarbital<br/>brallobarbital<br/>brotizolam<br/>butalbarbital<br/>pyrityldion (3,3-dietyl-2,4-dioxotetrahydropyridin)<br/>heptabarbital<br/>hexapropymat<br/>hexobarbital<br/>klometiazol<br/>kloralhydrat<br/>kloralodol<br/>metohexital<br/>metylpentynol<br/>midazolam<br/>tybamat<br/>vinbarbital<br/>zolpidem<br/>zopiclone<br/>fenazepam<br/>etizolam (4-(o-klorofenyl)-2-etyl-9-metyl-6H-tieno[3,2-f]-s-triazolo[4,3-</p> <p style="position:absolute;top:852px;left:181px;white-space:nowrap" class="ft40">a][1,4]diazepin)</p> <p style="position:absolute;top:886px;left:196px;white-space:nowrap" class="ft40">Som narkotika enligt narkotikastrafflagen ska �ven anses de ovanjordiska</p> <p style="position:absolute;top:904px;left:181px;white-space:nowrap" class="ft40">delarna av v�xten kat (Catha edulis) samt svamparna Psilocybe semilanceata</p> </div> <div id="page5-div" style="position:relative;width:701px;height:1028px;"> <img width="701" height="1028" src="/Static/i/lagboken/hidden.png" alt="background image"/> <p style="position:absolute;top:924px;left:649px;white-space:nowrap" class="ft50">5</p> <p style="position:absolute;top:51px;left:536px;white-space:nowrap" class="ft51"><b>SFS 2013:640</b></p> <p style="position:absolute;top:51px;left:77px;white-space:nowrap" class="ft55">(toppsl�tskivling) och Psilocybe cubensis. Detsamma ska g�lla andra svampar<br/>som inneh�ller �mnena psilocybin eller psilocin, om svamparna �r framod-<br/>lade eller om de har torkats eller p� annat s�tt beretts.</p> <p style="position:absolute;top:103px;left:91px;white-space:nowrap" class="ft50">Vidare ska vid till�mpning av lagen med cannabis f�rst�s de ovanjordiska</p> <p style="position:absolute;top:120px;left:77px;white-space:nowrap" class="ft55">delarna av varje v�xt av sl�ktet Cannabis (med undantag av fr�n), fr�n vilka<br/>hartset icke blivit extraherat och oavsett under vilka ben�mningar de f�re-<br/>kommer. Med cannabis ska dock inte f�rst�s hampa som</p> <p style="position:absolute;top:172px;left:91px;white-space:nowrap" class="ft50">1. �r av sort som kan ber�ttiga till st�d enligt r�dets f�rordning (EG) nr</p> <p style="position:absolute;top:190px;left:77px;white-space:nowrap" class="ft55">1782/2003 av den 29 september 2003 om uppr�ttande av gemensamma be-<br/>st�mmelser f�r system f�r direktst�d inom den gemensamma jordbruks-<br/>politiken och om uppr�ttande av vissa st�dsystem f�r jordbrukare och om<br/>�ndring av f�rordningarna (EEG) nr 2019/93, (EG) nr 1452/2001, (EG) nr<br/>1453/2001, (EG) nr 1454/2001, (EG) nr 1868/94, (EG) nr 1251/1999, (EG) nr<br/>1254/1999, (EG) nr 1673/2000, (EEG) nr 2358/71 och (EG) nr 2529/2001</p> <p style="position:absolute;top:275px;left:511px;white-space:nowrap" class="ft52">4,</p> <p style="position:absolute;top:294px;left:77px;white-space:nowrap" class="ft55">r�dets f�rordning (EG) nr 73/2009 av den 19 januari 2009 om uppr�ttande av<br/>gemensamma best�mmelser f�r system f�r direktst�d f�r jordbrukare inom<br/>den gemensamma jordbrukspolitiken och om uppr�ttande av vissa st�dsystem<br/>f�r jordbrukare, om �ndring av f�rordningarna (EG) nr 1290/2005, (EG) nr<br/>247/2006 och (EG) nr 378/2007 samt om upph�vande av f�rordning (EG) nr<br/>1782/2003</p> <p style="position:absolute;top:379px;left:137px;white-space:nowrap" class="ft52">5 och r�dets f�rordning (EG) nr 1673/2000 av den 27 juli 2000 om</p> <p style="position:absolute;top:399px;left:77px;white-space:nowrap" class="ft55">den gemensamma organisationen av marknaderna f�r lin och hampa som od-<br/>las f�r fiberproduktion</p> <p style="position:absolute;top:414px;left:205px;white-space:nowrap" class="ft52">6 och</p> <p style="position:absolute;top:433px;left:91px;white-space:nowrap" class="ft50">2. odlas efter det att ans�kan om direktst�d f�r s�dan odling enligt r�dets</p> <p style="position:absolute;top:451px;left:77px;white-space:nowrap" class="ft55">f�rordning (EG) nr 1782/2003 eller r�dets f�rordning (EG) nr 73/2009 givits<br/>in till beh�rig myndighet.</p> <p style="position:absolute;top:895px;left:77px;white-space:nowrap" class="ft53">4 EUT L 270, 21.10.2003, s. 1 (Celex 32003R1782).</p> <p style="position:absolute;top:908px;left:77px;white-space:nowrap" class="ft53">5 EUT L 30, 31.1.2009, s. 16 (Celex 32009R0073).</p> <p style="position:absolute;top:921px;left:77px;white-space:nowrap" class="ft53">6 EGT L 193, 29.7.2000, s.16 (Celex 32000R1673).</p> </div> <div id="page6-div" style="position:relative;width:701px;height:1028px;"> <img width="701" height="1028" src="/Static/i/lagboken/hidden.png" alt="background image"/> <p style="position:absolute;top:946px;left:529px;white-space:nowrap" class="ft60">Norstedts Juridik AB/Fritzes</p> <p style="position:absolute;top:956px;left:534px;white-space:nowrap" class="ft60">Elanders Sverige AB, 2013</p> </div> </div> ;